Alkermes Financial Statements
NASDAQ: ALKSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 1:57 PM ET
Alkermes revenue and earnings
In fiscal 2025, Alkermes generated $1.48 billion in revenue, down 5.2% from fiscal 2024, its first annual decline since 2024. Net income was $241.7 million (-34.2% year over year), for a net margin of 16.4% versus a median of -4.1% in the prior 5 years. Gross margin was 86.7% (up from 84.2%) and operating margin 17.2%.
Diluted earnings per share came in at $1.43, down from $2.17. Over the last 5 fiscal years, ALKS's revenue has grown at a 7.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Alkermes income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.48B | 1.56B | 1.66B | 1.11B | 1.17B | 1.04B | 1.17B | 1.09B | 903.37M | 745.69M |
| Revenue growth (YoY) | -5.25% | -6.36% | +49.61% | -5.28% | +13.00% | -11.29% | +7.01% | +21.13% | +21.15% | +18.68% |
| Cost of Revenue | 196.46M | 245.33M | 253.04M | 218.07M | 197.32M | 178.32M | 180.38M | 176.42M | 154.75M | 132.12M |
| Gross Profit | 1.28B | 1.31B | 1.41B | 893.73M | 976.43M | 860.44M | 990.56M | 917.85M | 748.63M | 613.57M |
| Operating Expenses | 1.03B | 891.66M | 996.25M | 899.82M | 878.68M | 972.87M | 1.17B | 1.02B | 896.53M | 822.24M |
| Research & Development | 323.96M | 245.33M | 270.81M | 272.70M | 290.92M | 394.59M | 512.83M | 425.41M | 412.89M | 387.15M |
| Selling, General & Admin | 701.52M | 645.24M | 689.75M | 590.75M | 549.61M | 538.83M | 599.45M | 526.41M | 421.58M | 374.13M |
| Operating Income | 253.96M | 420.64M | 414.12M | -6.09M | 97.75M | -112.43M | -175.48M | -99.13M | -147.90M | -208.66M |
| Interest Expense | 12.28M | 22.58M | 23.03M | 13.04M | 11.22M | 8.66M | 13.60M | 15.44M | 12.01M | 14.89M |
| Other Income (Expense) | 37.49M | 23.11M | 7.40M | -25.04M | -10.02M | 15.89M | -21.58M | -27.84M | 4.63M | -5.72M |
| Pretax Income | 291.45M | 443.75M | 421.52M | -31.13M | 87.73M | -96.54M | -197.06M | -126.97M | -143.27M | -214.39M |
| Income Tax | 49.79M | 71.61M | -97.64M | 2.02M | 11.33M | 14.32M | -436.00K | 12.34M | 14.67M | -5.94M |
| Net Income | 241.66M | 367.07M | 355.76M | -158.27M | -48.17M | -110.86M | -196.62M | -139.31M | -157.94M | -208.44M |
| Net Income growth (YoY) | -34.16% | +3.18% | — | — | — | — | — | — | — | — |
| EPS (Basic) | 1.47 | 2.22 | 2.14 | -0.97 | -0.30 | -0.70 | -1.25 | -0.90 | -1.03 | -1.38 |
| EPS (Diluted) | 1.43 | 2.17 | 2.10 | -0.97 | -0.29 | -0.70 | -1.25 | -0.90 | -1.03 | -1.38 |
| Shares Outstanding (Basic) | 164.70M | 165.39M | 166.22M | 163.74M | 160.94M | 158.80M | 157.05M | 155.11M | 153.41M | 151.48M |
| Shares Outstanding (Diluted) | 168.74M | 169.20M | 169.73M | 163.74M | 164.75M | 158.80M | 157.05M | 155.11M | 153.41M | 151.48M |
| EBITDA | 281.12M | 449.17M | 489.05M | 71.77M | 176.40M | -30.57M | -95.07M | 4.53M | -49.38M | -114.41M |
| Gross Margin | 86.69% | 84.25% | 84.79% | 80.39% | 83.19% | 82.83% | 84.59% | 83.88% | 82.87% | 82.28% |
| Operating Margin | 17.21% | 27.00% | 24.90% | -55.00% | 8.33% | -10.82% | -14.99% | -9.06% | -16.37% | -27.98% |
| Net Margin | 16.37% | 23.57% | 21.39% | -14.24% | -4.10% | -10.67% | -16.79% | -12.73% | -17.48% | -27.95% |
This table shows 10 annual periods of Alkermes's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ALKS's reporting calendar. What is a income statement?